Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priscila Nakasato

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Mediterranean Journal of Rheumatology|May 17, 2024
Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease ContinuumApostolos Kontzias, Olga Petryna, Priscila Nakasato, et al.
Therapeutic Advances in Musculoskeletal Disease|September 9, 2022
New insights on multigenic autoinflammatory diseasesPetros Efthimiou, Olga Petryna, Priscila Nakasato, et al.
Rheumatology and Therapy|January 19, 2022
Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease Treated with Canakinumab: Bayesian and Population Model-Based AnalysesCornelia Dunger-Baldauf, Priscila Nakasato, Stephanie Noviello, et al.
Clinical and Translational Science|November 20, 2023
Upadacitinib: Mechanism of action, clinical, and translational scienceMohamed-Eslam F Mohamed, Sumit Bhatnagar, Julie M Parmentier, et al.
Seminars in Arthritis and Rheumatism|June 27, 2021
Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapiesPetros Efthimiou, Apostolos Kontzias, Peter Hur, et al.
Rheumatology and Therapy|September 18, 2021
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled TrialsPhilip J Mease, Dafna D Gladman, Arthur Kavanaugh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 3, 2024
Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial SpondyloarthritisDenis Poddubnyy, Bhumik Parikh, Dirk Elewaut, et al.
Rheumatology and Therapy|December 7, 2021
Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World SettingsPeter Hur, Esther Yi, Raluca Ionescu-Ittu, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Mediterranean Journal of Rheumatology|May 17, 2024
Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease ContinuumApostolos Kontzias, Olga Petryna, Priscila Nakasato, et al.
Therapeutic Advances in Musculoskeletal Disease|September 9, 2022
New insights on multigenic autoinflammatory diseasesPetros Efthimiou, Olga Petryna, Priscila Nakasato, et al.
Rheumatology and Therapy|January 19, 2022
Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease Treated with Canakinumab: Bayesian and Population Model-Based AnalysesCornelia Dunger-Baldauf, Priscila Nakasato, Stephanie Noviello, et al.
Clinical and Translational Science|November 20, 2023
Upadacitinib: Mechanism of action, clinical, and translational scienceMohamed-Eslam F Mohamed, Sumit Bhatnagar, Julie M Parmentier, et al.
Seminars in Arthritis and Rheumatism|June 27, 2021
Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapiesPetros Efthimiou, Apostolos Kontzias, Peter Hur, et al.
Rheumatology and Therapy|September 18, 2021
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled TrialsPhilip J Mease, Dafna D Gladman, Arthur Kavanaugh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 3, 2024
Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial SpondyloarthritisDenis Poddubnyy, Bhumik Parikh, Dirk Elewaut, et al.
Rheumatology and Therapy|December 7, 2021
Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World SettingsPeter Hur, Esther Yi, Raluca Ionescu-Ittu, et al.
Pageof 1